World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
51613
World Ranking
5494
National Ranking
2961

Walter M. Stadler publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Walter M. Stadler sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 597 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Walter M. Stadler D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Walter M. Stadler sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Walter M. Stadler is affiliated with the University of Chicago in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with notable contributions in subfields such as Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Economics and Econometrics.

The scientist's work focuses on several key topics, including:

  • Renal cell carcinoma treatment
  • Prostate Cancer Treatment and Research
  • Renal and related cancers
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Pancreatic and Hepatic Oncology Research
  • Radiopharmaceutical Chemistry and Applications

Walter M. Stadler has contributed to multiple peer-reviewed research papers. Among their recent publications are:

  • Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma, 2022, JAMA Oncology
  • Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE), 2020, Journal of Clinical Oncology
  • Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma, 2024, New England Journal of Medicine
  • Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer, 2022, JAMA Oncology
  • Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC), 2021, Cancer

Their frequent co-authors include:

  • Russell Z. Szmulewitz
  • Christian Kollmannsberger
  • Toni K. Choueiri
  • Laurence Albigès
  • Brian I. Rini

Publications by Walter M. Stadler appear notably in the following venues:

  • Journal of Clinical Oncology
  • Cancer
  • Clinical Cancer Research
  • JAMA Oncology
  • Clinical Genitourinary Cancer

Best Publications

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

    Michael B. Atkins;Manuel Hidalgo;Walter M. Stadler;Theodore F. Logan

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

    Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Ezra E. W. Cohen;Fred Rosen;Walter M. Stadler;Wendy Recant

  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

    Eric J. Small;Susan Halabi;Nancy A. Dawson;Walter M. Stadler

  • Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

    Naomi B. Haas;Judith Manola;Robert G. Uzzo;Keith T. Flaherty

  • Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

    Hedy L. Kindler;Gregory Friberg;Deepti A. Singh;Gershon Locker

  • Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers

    Gladell P. Paner;Walter M. Stadler;Donna E. Hansel;Rodolfo Montironi

  • Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663

    Mary-Ellen Taplin;Barur Rajeshkumar;Susan Halabi;Cary P. Werner

  • Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells

    Henry K. Lin;Siyang Zheng;Anthony J. Williams;Marija Balic

  • Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

    B. Escudier;C. Szczylik;T. Eisen;W. M. Stadler

  • Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

    Daniel V.T. Catenacci;Melissa R. Junttila;Theodore Karrison;Nathan Bahary

  • Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

    Brian I. Rini;M. Dror Michaelson;Jonathan E. Rosenberg;Ronald M. Bukowski

  • Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

    Brian I. Rini;George Wilding;Gary Hudes;Walter M. Stadler

Frequent Co-Authors

Theodore Karrison
Theodore Karrison University of Chicago
Mark J. Ratain
Mark J. Ratain University of Chicago
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Susan Halabi
Susan Halabi Duke University
Ronald M. Bukowski
Ronald M. Bukowski Cleveland Clinic
Toni K. Choueiri
Toni K. Choueiri Harvard University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Everett E. Vokes
Everett E. Vokes University of Chicago
Daniel J. George
Daniel J. George Duke University
Eric J. Small
Eric J. Small University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Medicine opens doors to numerous online education and career options in the healthcare field. For those interested in medical administration, medical billing and coding classes online offer a fast-track into back-office healthcare roles, providing foundational knowledge at a flexible pace and often at an affordable cost.

If your career goals involve becoming an advanced practice nurse, consider the cheapest np school online. Online nurse practitioner programs combine rigorous coursework with accessible online formats, allowing you to balance studies with work or family commitments.

For registered nurses aiming to advance their education, explore the cheapest online msn programs. These degrees help expand your expertise in specialized nursing fields and open up leadership roles.

Want to reach the highest level in nursing? The cheapest dnp programs online are ideal for those looking to lead, teach, or influence health policy and practice. Each online pathway offers unique advantages, helping you build a meaningful and successful healthcare career.

Best Scientists Citing Walter M. Stadler

Trending Scientists

Recently Published Articles